Neurokinin-1 receptor antagonists for prevention of chemotherapy-related nausea and vomiting

Cochrane Database of Systematic Reviews

Volumn , Issue 4, 2007, Pages

  Tremont Lukats, Ivo W ^a   Bruera, E E ^b   Gonzalez Barboteo J ^b  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 (3 OXO 1 PHOSPHORYL 1,2,4 TRIAZOL 5 YLMETHYL)MORPHOLINE; 3 (2 METHOXYBENZYLAMINO) 2 PHENYLPIPERIDINE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CASOPITANT; CORTICOSTEROID DERIVATIVE; DEXAMETHASONE; EZLOPITANT; GRANISETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PALONOSETRON; PLACEBO; SUBSTANCE P; VOFOPITANT;

CLINICAL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DATA SYNTHESIS; DRUG EFFICACY; HUMAN; INFORMATION PROCESSING; INTERVENTION STUDY; MEDICAL RESEARCH; NAUSEA AND VOMITING; PROPHYLAXIS; PROSPECTIVE STUDY; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 44949229235     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006844     Document Type: Review

References (15)

1. Aapro 1993 Aapro MS. Review of experience with ondansetron and granisetron. Annals of Oncology 1993;4(Suppl 3):9-14.
2. Bleiberg 2000 Bleiberg H. A new class of antiemetics: the NK-1 receptor antagonists. Current Opinion in Oncology 2000;12(4):284- 8.
3. Bloechl-Daum 2006 Bloechl-Daum B, Deuson RR, Mavros P, Hansen M, Herrstedt J. Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment. Journal of Clinical Oncology 2006;24(27):4472-8.
4. Coates 1983 Coates A, Abraham S, Kaye SB, Sowerbutts T, Frewin C, Fox RM. On the receiving end - patient perception of the side-effects of cancer chemotherapy. European Journal of Cancer and Clinical Oncology 1983;19(2):203-8.
5. Gralla 1999 Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al.Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. Journal of Clinical Oncology 1999;17:2971-94.
6. Herrstedt 2002 Herrstedt J. Nausea and emesis: still an unsolved problem in cancer patients?. Supportive Care in Cancer 2002;10:85-7.
7. Hesketh 1998 Hesketh PJ, Gralla RJ, du Bois A, Tonato M. Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity. Supportive Care in Cancer 1998;6(3):221-7.
8. Hickok 2003 Hickok JT, Roscoe JA, Morrow GR, King DK, Atkins JN, Fitch TR. Nausea and emesis remain significant problems of chemotherapy despite prophylaxis with 5-hydroxytryptamine-3 antiemetics: a University of Rochester James P. Wilmot Cancer Center Community Clinical Oncology Program Study of 360 cancer patients treated in the community. Cancer 2003;97(11):2880- 6.
9. Higgins 2006 Higgins J, Green S (editors). Aproaches to summarising the validity of studies. Cochrane handbook for systematic reviews of interventions 4.2.5. Chichester, UK: John Wiley & Sons, (updated September 2006). http://www.cochrane.dk/cochrane/handbook/handbook.htm: (accessed 7/30/2007).
10. Kris 1997 Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. Journal of the National Cancer Institute 1997;89(11): 817-8.
11. Kris 2005 Kris MG, Hesketh PJ, Herrstedt J, Rittenberg C, Einhorn LH, Grunberg S, et al.Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Supportive Care in Cancer 2005;13(2):85-96.
12. Kris 2006 Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, et al.American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. Journal of Clinical Oncology 2006;24(18):2932-47.
13. Morrow 1998 Morrow GR, Ballatori E, Groshen S, Olver I. Statistical considerations in the design, conduct, and analyses of antiemetic clinical trials. Supportive Care in Cancer 1998;6:261-5.
14. Navari 2004 Navari RM. Aprepitant: a neurokinin-1 receptor antagonist for the treatment of chemotherapy-induced nausea and vomiting. Expert Review of AntiCancer Therapy 2004;4(5):715-24.
15. Saito 2003 Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. Journal of Pharmacological Sciences 2003;91(2):87-94.